MTOR and ovarian cancer: This result is consistent with our previous in vitro data identifying BCL2 as a component of the adaptive response to PI3K/mTOR inhibition in ovarian cancer cells.1 To determine whether BCL2 was induced throughout the entire tumor or specifically enriched in the protected outer cells, we performed BCL2 IHC analysis on matched tumor tissue sections (Fig. 2).